Cystic Fibrosis: Pathophysiology of Lung Disease
- PMID: 31659725
- DOI: 10.1055/s-0039-1694021
Cystic Fibrosis: Pathophysiology of Lung Disease
Abstract
Cystic fibrosis (CF) is a common, life-threatening, multisystemic, autosomal recessive disorder. In the last few years, giant steps have been made with regard to the understanding of CF pathophysiology, allowing the scientific community to propose mechanisms that cause the myriad of CF clinical manifestations. Following the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989, the structure and function of the CFTR protein were described. Since then, more than 2,000 variants of the CFTR gene and their impact on the amount and function of the CFTR protein have been reported. The role of the CFTR protein as an ion channel transporting chloride and bicarbonate and its repercussions on different epithelial cell-lined organs and mucus are now better understood. Mechanisms behind susceptibility to infection in CF have also been proposed and include abnormalities in the composition, volume and acidity of the airway surface liquid, changes in the submucosal gland's anatomy and function, and deficiencies in the mucociliary clearance system. Numerous hypotheses explaining the excessive inflammatory response in CF are also debated and involve impaired mucociliary clearance, persistent hypoxia, lipid abnormalities, protease and antiprotease disproportion, and oxidant and antioxidant imbalance. The purpose of this review is to summarize our current knowledge of CF pathophysiology, including significant historic discoveries and most recent breakthroughs, and to improve understanding and awareness of this fatal disease.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Conflict of interest statement
Dr. Cantin reports personal fees from Vertex Pharmaceuticals, outside the submitted work.
Similar articles
-
Role of CFTR in airway disease.Physiol Rev. 1999 Jan;79(1 Suppl):S215-55. doi: 10.1152/physrev.1999.79.1.S215. Physiol Rev. 1999. PMID: 9922383 Review.
-
Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.Methods Mol Biol. 2011;742:3-14. doi: 10.1007/978-1-61779-120-8_1. Methods Mol Biol. 2011. PMID: 21547723
-
Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.Thorax. 2016 Mar;71(3):284-7. doi: 10.1136/thoraxjnl-2015-207588. Epub 2015 Dec 30. Thorax. 2016. PMID: 26719229 Review.
-
Ion channels as targets to treat cystic fibrosis lung disease.J Cyst Fibros. 2018 Mar;17(2S):S22-S27. doi: 10.1016/j.jcf.2017.10.006. Epub 2017 Nov 6. J Cyst Fibros. 2018. PMID: 29102290 Review.
-
Chloride Conductance, Nasal Potential Difference and Cystic Fibrosis Pathophysiology.Lung. 2020 Feb;198(1):151-156. doi: 10.1007/s00408-019-00293-6. Epub 2019 Nov 16. Lung. 2020. PMID: 31734731
Cited by
-
Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.J Fungi (Basel). 2024 Sep 18;10(9):656. doi: 10.3390/jof10090656. J Fungi (Basel). 2024. PMID: 39330416 Free PMC article. Review.
-
Insights into Aspergillus fumigatus Colonization in Cystic Fibrosis and Cross-Transmission between Patients and Hospital Environments.J Fungi (Basel). 2024 Jun 29;10(7):461. doi: 10.3390/jof10070461. J Fungi (Basel). 2024. PMID: 39057346 Free PMC article.
-
Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies.Adv Respir Med. 2024 Jul 20;92(4):263-277. doi: 10.3390/arm92040026. Adv Respir Med. 2024. PMID: 39051188 Free PMC article. Review.
-
Pseudomonas aeruginosa Lipid A Structural Variants Induce Altered Immune Responses.Am J Respir Cell Mol Biol. 2024 Aug;71(2):207-218. doi: 10.1165/rcmb.2024-0059OC. Am J Respir Cell Mol Biol. 2024. PMID: 38656811
-
Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.ACS Pharmacol Transl Sci. 2024 Mar 14;7(4):933-950. doi: 10.1021/acsptsci.3c00362. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633590 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical